Rootsi - rootsi - Läkemedelsverket (Medical Products Agency)

ecuphar nv - metronidazol - tablett - 250 mg - metronidazol 250 mg aktiv substans - hund, katt

Rootsi - rootsi - Läkemedelsverket (Medical Products Agency)

ecuphar nv - metronidazol - tablett - 500 mg - metronidazol 500 mg aktiv substans - hund, katt

Rootsi - rootsi - Läkemedelsverket (Medical Products Agency)

ecuphar nv - doxycyklinhyklat - tablett - 40 mg - doxycyklinhyklat 47,88 mg aktiv substans - hund, katt

Rootsi - rootsi - Läkemedelsverket (Medical Products Agency)

ecuphar nv - doxycyklinhyklat - tablett - 200 mg - doxycyklinhyklat 239,4 mg aktiv substans - hund, katt

Rootsi - rootsi - Läkemedelsverket (Medical Products Agency)

ecuphar veterinaria s.l.u - etamsylat - injektionsvätska, lösning - 125 mg/ml - etamsylat 125 mg aktiv substans; natriummetabisulfit hjälpämne; natriumsulfit (vattenfritt) hjälpämne; bensylalkohol hjälpämne - får, get, hund, häst, katt, nöt, svin

Rootsi - rootsi - Läkemedelsverket (Medical Products Agency)

ecuphar nv - tiamazol - oral lösning - 10 mg/ml - sorbitol hjälpämne; glycerol hjälpämne; tiamazol 10 mg aktiv substans - katt

Rootsi - rootsi - Läkemedelsverket (Medical Products Agency)

ecuphar nv - isofluran - inhalationsånga, vätska - 1000 mg/g - isofluran 1000 mg aktiv substans - burfåglar, chinchilla, gerbil, hamster, hund, häst, iller, katt, marsvin, mus, reptiler, råtta

Rootsi - rootsi - Läkemedelsverket (Medical Products Agency)

ecuphar nv - natriumklorid - injektions-/infusionsvätska, lösning - 9 mg/ml - natriumklorid 9 mg aktiv substans - samtliga

Rootsi - rootsi - Läkemedelsverket (Medical Products Agency)

ecuphar nv - kalciumkloriddihydrat; kaliumklorid; natriumklorid; natriumlaktatlösning - infusionsvätska, lösning - natriumlaktatlösning aktiv substans; natriumklorid 6 mg aktiv substans; kaliumklorid 0,4 mg aktiv substans; kalciumkloriddihydrat 0,27 mg aktiv substans - samtliga

Euroopa Liit - rootsi - EMA (European Medicines Agency)

sandoz gmbh - rituximab - lymphoma, non-hodgkin; arthritis, rheumatoid; microscopic polyangiitis; wegener granulomatosis - antineoplastiska medel - riximyo is indicated in adults for the following indications:non-hodgkin’s lymphoma (nhl)riximyo is indicated for the treatment of previously untreated adult patients with stage iii-iv follicular lymphoma in combination with chemotherapy. riximyo maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy. riximyo monotherapy is indicated for treatment of adult patients with stage iii-iv follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy. riximyo is indicated for the treatment of adult patients with cd20 positive diffuse large b cell non-hodgkin’s lymphoma in combination with chop (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy. riximyo in combination with chemotherapy is indicated for the treatment of paediatric patients (aged ≥ 6 months to < 18 years old) with previously untreated advanced stage cd20 positive diffuse large b-cell lymphoma (dlbcl), burkitt lymphoma (bl)/burkitt leukaemia (mature b-cell acute leukaemia) (bal) or burkitt-like lymphoma (bll). chronic lymphocytic leukaemia (cll)riximyo in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. endast begränsade data finns tillgängliga om effekten och säkerheten för patienter som tidigare behandlats med monoklonala antikroppar inklusive rituximab eller patienter med refraktära mot tidigare rituximab plus kemoterapi. se avsnitt 5. 1 för ytterligare information. rheumatoid arthritisriximyo in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-modifying anti-rheumatic drugs (dmard) including one or more tumour necrosis factor (tnf) inhibitor therapies. rituximab har visat sig minska risken för progression av ledskador mätt med röntgen och förbättra den fysiska funktionen, när det ges i kombination med metotrexat. granulomatosis with polyangiitis and microscopic polyangiitisriximyo, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (wegener’s) (gpa) and microscopic polyangiitis (mpa). riximyo, in combination with glucocorticoids, is indicated for the induction of remission in paediatric patients (aged ≥ 2 to < 18 years old) with severe, active gpa (wegener’s) and mpa. pemphigus vulgarisriximyo is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (pv).